NR1I2 and malignant colon neoplasm: Nevertheless, our results provide a novel insight into how PXR, in a ligand-independent and nongenomic manner, may be suppressing p53 function in response to chemotherapeutic drugs, rescuing colon cancer cells from drug toxicity, and thus promoting malignant transformation.